{"prompt": "['21] Nelius T et al: Clinical outcome of patients with docetaxel resistant hormone refractory', 'prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med', 'Oncol 2010;27:363-7', '22) Ladoire S et al: metronomic oral cyclophosphamide prednisolone chemotherapy is an', 'effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.', 'Anticancer Res 2010;30;4317-4324', '23] Lord R et al: Low dose metronomic oral cyclophosphamide for hormone resistant prostate', 'cancer: a phase II study. J. Urol 2007;177:2136-40', '24] Fontana A et al: Metronomic cyclophosphamide in elderly patients with advanced,', 'castration resistant prostate cancer. J. Geriatrics Am. Soc. 2010;58:986-7', '25] Kummar S et al: A phase I study of veliparib in combination with metronomic', 'cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res', '2012;18:1726-34', '26] Mayer EL et al: Combination antiangiogenic therapy in advanced breast cancer: a phase I', 'trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet', 'proteomics. Breast Cancer Res Treat DOI 10.1007/s10549-012-2256-5', '27] Orlando L et al: Prolonged clinical benefit with metronomic chemotherapy in patients with', 'metastatic breast cancer. Anticancer Drugs 2006;17:961-967', '28] Garcia A et al: Phase II clinical trial of bevacizumab and low dose metronomic', 'cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess', 'Margaret Hospital phase II consortia. J. Clin. Oncol. 2008:26:135-41', '29] Toulmonde M et al: Use of PD-1 Targeting, Macrophage Infiltration, and IDO pathway', 'activation in sarcomas, a phase 2 clinical trial. JAMA Oncol 2017', 'doi:10.1001/jamaoncol.2017.1617', '30] Haikerwal S.J. et al:Building immunity to cancer with radiation therapy. Cancer letters', '2015;368:198-208', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '50']['31/ Chi K.H. et al: Combination of conformal radiotherapy and intratumoral injection of', 'adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 2005;28:185-193', '32) Chandra RA et al: A systematic evaluation of abscopal responses following radiotherapy in', 'patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015;4:e1046028', '33] Aboudaram A et al: Concurrent radiotherapy for patients with metastatic melanoma and', 'receiving anti-programmed -death 1 therapy: a safe and effective combination. Melanoma Res', '2017;27:485-491', '34) De la Cruz-Merino L et al: Radiation for awakening the dormant immune system, a', 'promising challenge to be explored. Front. Immunol. 2014;5:102', '35]', 'Quesnel B.: Tumor dormancy and immunoescape. APMIS 2008; 116:685-94', '36] Greenberg PD et al: Pillars article: Eradication of disseminated murine leukemia by', 'chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-', 'J+2-lymphocytes. J. Immunol 2013; 190;1899-910', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '51']['13.0 SUPPORTING DOCUMENTATION', 'Appendix I SAE Form Motal FAC-SIMILE', 'G.O.N.O.', 'Serious Adverse Event Report Form', 'COMPANY USE ONLY', 'Gruppo Oncologico Nord', '(Investigator Sponsored Study)', 'Receipt date of this report', 'Ovest', '(stamp or date)', 'PI Marco Carlo Merlano', 'Version N\u00b01.0 - Date:18/12/2017', 'TYPE OF REPORT', 'N\u00b0 EudraCT: 2017-000353-39', 'Initial', 'Follow-up', 'CONFRONT Trial', 'A. REPORTER INFORMATION', \"Reporter's First Name\", \"Reporter's Last Name\", \"Investigator's First Name (if different from Reporter)\", \"Investigator's Last Name (if different from Reporter)\", 'Address', 'City', 'Country', 'Phone Number', 'E-Mail:', 'Fax Number', 'B. SUBJECT INFORMATION', 'Subject ID', 'Center No.', 'Subject No.', 'Subject Initials', 'Sex', 'Height', 'Weight', 'NA', 'Female', 'Male', 'cm', 'kg', 'Date of Birth (dd/mmm/yyyy)', 'OR', 'Age at Time of Adverse Event (Specify unit, e.g. years months, etc.)', '/', '/', 'Ethnicity/Race', 'American Indian/Alaska native', 'Asian', 'Black or African American', 'Caucasian/White', 'Hispanic or Latino', 'Native Hawaiian or other Pacific islander', 'other', 'C. RELEVANT MEDICAL HISTORY', 'Start Date', 'End Date', 'Condition/Disorder', '(dd/mmm/yyyy)', '(dd/mmm/yyyy)', '/', '/', '/ /', '/ /', '/ /', '/ /', '/ /', '/ /', '/ /', '/', '/', '/ /', 'D. CONCOMITANT MEDICATIONS', 'Frequency of', 'Drug Trade Name', 'Route', 'Start Date', 'Single Dose', 'Stop Date', 'Indication', 'Administration', '(dd/mmm/yyyy)', '(dd/mmm/yyyy)', '/', '/', '/', '/', '/', '/', '/', '/', '/', '/', '/', '/', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '52']\n\n###\n\n", "completion": "END"}